Reaction
Biliary Tract Disorder reporting signals
As of the last recalculation, Biliary Tract Disorder appears in 1,359 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is OLANZAPINE PAMOATE (PRR 19.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Olanzapine Pamoate | 51 | 19.8 | 19.8 |
| Ursodiol | 24 | 17.2 | 17.2 |
| Ursosiol | 20 | 16.0 | 16.0 |
| Basiliximab | 11 | 14.4 | 14.4 |
| Valganciclovir Hydrochloride Powder, | 10 | 12.6 | 12.7 |
| Amoxicillin And Clavulanate Potassium | 22 | 12.6 | 12.6 |
| Norepinephrine | 8 | 11.5 | 11.5 |
| Valganciclovir | 14 | 11.5 | 11.5 |
| Valganciclovir Hydrochloride | 14 | 11.5 | 11.5 |
| Norepinephrine Bitartrate | 9 | 9.6 | 9.6 |
| Tacrolimus | 92 | 9.6 | 9.6 |
| Anti-Thymocyte Globulin (Rabbit) | 5 | 9.5 | 9.5 |
| Drospirenone And Ethinyl Estradiol | 23 | 8.1 | 8.1 |
| Durvalumab | 10 | 7.6 | 7.6 |
| Tolvaptan | 7 | 7.4 | 7.4 |
| Ado-Trastuzumab Emtansine | 4 | 7.3 | 7.3 |
| Micafungin Sodium | 4 | 7.2 | 7.2 |
| Pancrelipase | 18 | 7.2 | 7.2 |
| Atezolizumab | 18 | 7.2 | 7.2 |
| Gemcitabine | 18 | 7.1 | 7.1 |
| Gemcitabine Hydrochloride | 22 | 6.4 | 6.4 |
| Rifaximin | 7 | 5.1 | 5.1 |
| Erlotinib Hydrochloride | 4 | 4.9 | 4.9 |
| Irinotecan Hydrochloride | 4 | 4.8 | 4.8 |
| Erlotinib | 3 | 4.8 | 4.8 |
| Orlistat | 7 | 4.2 | 4.2 |
| Lenvatinib | 8 | 3.8 | 3.8 |